Please ensure Javascript is enabled for purposes of website accessibility

3 Best-Performing Dividend Aristocrats of 2020 So Far

By Keith Speights - May 6, 2020 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can their momentum continue?

We can pretty much sum up the stock market's performance in 2020 in just three letters: ugh. The COVID-19 pandemic has caused most stocks to sink. Even with the market rebound in recent weeks, there are more stocks with negative year-to-date returns than there are with positive returns.

This is true even for the elite group of stocks known as Dividend Aristocrats, members of the S&P 500 index that have increased their dividends for at least 25 consecutive years. But not all of these dividend favorites have fared poorly. Here are the three best-performing Dividend Aristocrats of 2020 so far -- and whether or not their momentum is likely to continue.

A gold crown on top of stacks of $100 bills.

Image source: Getty Images.

1. Clorox

Clorox (CLX 0.59%) ranks as the biggest year-to-date winner among Dividend Aristocrats. And it's not a close contest. The consumer staples stock has soared more than 30% so far in 2020. 

It's pretty easy to figure out why Clorox stock has performed so well. The COVID-19 pandemic is spurring people across the world to wipe down and disinfect surfaces like never before. This trend definitely showed up in Clorox's fiscal 2020 third-quarter results announced last week. The company reported a 32% increase in sales of its cleaning products. And its pre-tax profits from cleaning products soared 71% year over year.

There's no reason to expect that Clorox won't be able to keep on delivering strong sales growth throughout the rest of this year and into 2021. Until there's a safe and effective COVID-19 vaccine that's widely available, frequently wiping off surfaces will almost certainly remain part of everyday life.

After its surge this year, though, Clorox stock isn't cheap. Shares trade at nearly 28 times expected earnings. But with its must-have products and a nice dividend yield of 2.2%, it won't be surprising if Clorox keeps on wiping up the competition among Dividend Aristocrats.

2. S&P Global

S&P Global (SPGI 0.29%) is a true outlier among stocks in the financial sector, with its shares rising close to 8% year to date. Most financial stocks have fallen in 2020.

The differentiator for S&P Global is that it doesn't face risks from loan defaults as banks do. Instead, the company makes its money by selling data and analytics to clients. Business is booming. S&P Global reported year-over-year revenue growth of 14% in its first quarter and easily beat the consensus Wall Street earnings estimate.

Unfortunately for S&P Global, though, the good times might not keep rolling much longer. The company expects that its customers will be increasingly impacted by the economic fallout of the efforts taken to slow the spread of COVID-19. S&P Global looks for new sales, and renewals of subscriptions by existing customers will be negatively affected by the pandemic and its aftermath.

S&P Global is even more pricey than Clorox, with its shares trading at nearly 29 times expected earnings. While the company's track record of 47 consecutive years of dividend increases is impressive, its dividend yield of less than 1% isn't anything to get excited about. 

3. Abbott Labs

Abbott Labs (ABT -0.83%) isn't too far behind S&P Global. The healthcare giant's share price has risen around 7% so far this year.

Although Abbott's medical device business has taken a hit as hospitals delayed non-emergency procedures due to the COVID-19 outbreak, its other units have fared quite well. Abbott beat analysts' revenue and earnings estimates in its first-quarter results thanks to strong international established pharmaceuticals sales and solid growth for its nutritional products business.

The company's future prospects appear bright. Abbott claims a lead spot among COVID-19 diagnostics systems makers, launching the fastest point-of-care test for diagnosing the novel coronavirus disease in March. The company's Alinity line of lab diagnostics systems and its MitraClip devices for leaky heart valves continue to enjoy strong sales momentum. Abbott also awaits a key FDA approval for a new version of its popular FreeStyle Libre continuous glucose monitoring (CGM) system.

These factors have propelled Abbott Labs stock to a lofty valuation, with shares trading at 32 times expected earnings. However, analysts look for the company to deliver average annual earnings growth of more than 10% over the next five years. That level of growth combined with a dividend yield of 1.6% should keep the stock on investors' radar screens.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$109.30 (-0.83%) $0.92
The Clorox Company Stock Quote
The Clorox Company
$144.75 (0.59%) $0.85
S&P Global Inc. Stock Quote
S&P Global Inc.
$344.32 (0.29%) $0.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.